Powered by HealthTechMovers.com
We added 3 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Insmed Incorporated, INSM
Summary: Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
- Last Price: $24.93
- Price Change: $-0.52, -2.04%
- Yearly Gain: 29.37%
- Market Cap: $3.70B
- P/E Ratio: -4.67
Here are 3rd party ratings for INSM:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 36% (89 out of 250)
What is the sentiment on the street regarding Insmed Incorporated ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Buying
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in INSM or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on INSM before you decide to make any investment.
Click here for chart >>
Ligand Pharmaceuticals Incorporated, LGND
Summary: Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.
- Last Price: $85.77
- Price Change: $0.48, 0.56%
- Yearly Gain: 10.54%
- Market Cap: $1.54B
- P/E Ratio: 16.03
Here are 3rd party ratings for LGND:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 36% (89 out of 250)
What is the sentiment on the street regarding Ligand Pharmaceuticals Incorporated ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Buy
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in LGND or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on LGND before you decide to make any investment.
Click here for chart >>
Elanco Animal Health Incorporated, ELAN
Summary: Elanco Animal Health Incorporated operates as an animal health care company. It develops, manufactures and markets products for companion and food animals. Elanco Animal Health Incorporated is based in Greenfield, United States.
- Last Price: $17.04
- Price Change: $-0.03, -0.18%
- Yearly Gain: 91.46%
- Market Cap: $8.42B
- P/E Ratio: -6.43
Here are 3rd party ratings for ELAN:
- TipRanks.com: Hold
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 22% (56 out of 250)
What is the sentiment on the street regarding Elanco Animal Health Incorporated ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in ELAN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ELAN before you decide to make any investment.
Click here for chart >>
Thanks for reading!
